Key Takeaways Mesenchymal stem cells (MSCs) have been tested in small rheumatoid arthritis (RA) trials, but no trial shows they stop the disease for good. A 2019 study of 64 people with RA reported lower disease scores at one and three years after umbilical cord cell infusion. A 2017 placebo-controlled
Key Takeaways Mesenchymal stem cell (MSC) therapy has been tested in small human trials for chronic lung inflammation, but none show it reverses lung scarring. A 2013 randomized trial of 62 people with chronic obstructive pulmonary disease (COPD) found no lung function gain from infused MSCs. A 2020 randomized trial
Key Takeaways A phase 3 trial led by the University of Wisconsin-Madison kept 15 of 20 treated recipients off anti-rejection drugs for over two years. The therapy uses blood-forming stem cells from the same sibling who donates the kidney. None of the 20 treated recipients developed graft-versus-host disease. Only closely
Key Takeaways Two phase 3 trials tested the same stem cell injection for complex Crohn’s perianal fistulas, separated by a decade. The first trial, ADMIRE-CD, showed a clear benefit and led to European approval in 2018. ADMIRE-CD II, a much larger follow-up trial, enrolled 568 patients and found no real
Key Takeaways Most trials do not measure meaningful change until at least one month, with pain relief typically building gradually through 3 to 6 months. By 12 months, trial data show improvements in both pain and function, with dose and cell source affecting how strong and how long-lasting that benefit
Key Takeaways A 2024 network meta-analysis of 48 studies ranked PRP highest for knee osteoarthritis pain and function, followed by a bone marrow cell-based option, then hyaluronic acid (HA). The cell-based option’s ranking rests on far fewer studies (2.5% of the pooled evidence) than HA’s ranking (nearly 41%), so that
Key Takeaways Stem cells for disc degeneration can be delivered in two ways: intradiscal injection straight into the disc, or IV infusion through a vein. A 2014 mouse study found intradiscal injection preserved disc height better, while IV delivery still boosted some tissue-repair markers without that structural effect. Cyrona Cell
Key Takeaways Chronic, low-grade inflammation and insulin resistance drive each other in a two-way loop that starts largely in visceral fat. Mesenchymal stem cells are being studied for their ability to calm this inflammation and support insulin sensitivity, not to replace diet, exercise, or medication. A 2022 randomized trial found
Key Takeaways Stem cell therapy for rheumatoid arthritis has real human trial data behind it, not just lab or animal studies. A 3-year study found that disease activity scores significantly decreased in patients who received stem cells alongside standard medication. Mesenchymal stem cells appear to calm the immune response that
Key Takeaways Stem cell therapy for psoriasis is being studied for its ability to calm the immune system, not just treat visible skin symptoms. Mesenchymal stem cells appear to shift the balance between two immune cell types, easing the overactive response behind psoriasis. A real phase 1/2a human trial using
